Mymetics Corp (MYMX)

[Work Harder]

Robbins Arroyo LLP: DBV Technologies S.A. (DBVT) Sued for Misleading Shareholders

https://www.businesswire.com/news/home/20190204005687/en/Robbins-Arroyo-LLP-DBV-Technologies-S.A.-DBVT

According to the complaint, in February 2018, DBV announced that the U.S. Food and Drug Administration ("FDA") agreed that the efficacy and safety data for DBV's drug, Viaskin Peanut, supported the submission of a Biologics License Application ("BLA"). In October 2018, DBV stated that the company submitted its BLA, calling it a "significant step forward for those families living with peanut allergy." It came as a surprise to investors when, less than two months later, DBV announced that it voluntarily withdrew its BLA because the FDA determined that the level of detail for manufacturing procedures and quality controls was insufficient. On this news, DBV shares plummeted nearly 60% to close at $5.76 per share on December 20, 2018.